About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Articles

Levosimendan in Europe and China

Published:

08 November 2021

Citation:

European Cardiology Review 2021;16:e42.

Women and Diabetes: Preventing Heart Disease in a New Era of Therapies

Published:

21 October 2021

Citation:

European Cardiology Review 2021;16:e40.

Evaluation of the Effect of Heart Failure Reversal Therapy on Exercise Capacity in Patients with Chronic Heart Failure and the Association with Co-morbidities

Citation:

European Cardiology Review 2020;15:e39.

Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

Published:

18 December 2019

Citation:

European Cardiology Review 2019;14(3):201